Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial

Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial

Abstract The licensed adjuvanted recombinant glycoprotein E (gE) subunit vaccine (HZ/su) is highly effective against herpes zoster (HZ). This randomised, active-controlled, non-inferiority trial (ChiCTR2300079076) compared the immunogenicity and safety of a novel gE-Fc fusion protein vaccine candida...

Full description

Saved in:
Bibliographic Details
Main Authors: Peng-Fei Jin, Ya-Ru Quan, Shi-Xin Xiu, Xian-Min Jiang, Hong-Xing Pan, Yuan Shen, Xu-Wen Wang, Jian Kong, Wen-Juan Wang, Xiang Cao, Kang-Wei Xu, Min Yang, Kun Yang, Wen-Yan Wan, Kai-Qin Wang, Li Chen, Ai-Hua Yao, Yu-Peng Xue, Na Wan, Ming Xu, Shi-Yao Tao, Ling Peng, Fang-Rong Yan, Chang-Gui Li, Jing-Xin Li
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-62800-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-62800-z

Similar Items